Considering the diverse benefits of GLP-1 on hyperglycemia, food intake, and even β cell function, Rg3 has possibility to be developed as a novel therapeutic agent for type 2 diabetes and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.